New GSK WKN: A3DMB5 ISIN: GB00BN7SWP63 Kürzel: GSK Forum: Aktien User: o2kuh

GSK plc announced promising results from its DREAMM-7 phase III trial, highlighting that its drug Blenrep, combined with bortezomib and dexamethasone, significantly improves survival rates for patients with relapsed or refractory multiple myeloma compared to standard treatments. These findings are set to be presented at the upcoming American Society of Hematology Annual Meeting and have bolstered GSK’s efforts to secure regulatory approval across various regions. Investors might find these developments encouraging as they underscore GSK’s potential impact on the oncology market. 🚀

Mal bisschen aufgestockt.

Jupp, ich auch

Dito.... Eigentlich ist meine Pos. voll....eigentlich...

Nicht super erquickend, aber immer noch verkraftbar

https://de.marketscreener.com/kurs/aktie/GSK-PLC-9590199/news/GSK-senkt-Umsatzprognose-fur-Impfstoffe-2024-48200016/

Total Q3 2024 sales £8.0 billion -2% AER; +2% CER • Vaccines sales -15%. Shingrix -7% and Arexvy -72% reflecting ACIP guideline changes, prioritisation of COVID vaccinations in the US and annualisation of Arexvy launch in Q3 2023 • Specialty Medicines sales +19%. HIV sales +12%. Oncology +94%. Respiratory/Immunology and other +14% • General Medicines sales +7%. Trelegy +16% • Total operating profit -86% and Total EPS -100% driven by a charge of £1.8 billion ($2.3 billion) in relation to the Zantac settlement • Core operating profit +5% and Core EPS +5% reflecting strong Specialty Medicines performance, together with effective cost management • Cash generated from operations in the quarter £2.5 billion with Free cash flow of £1.3 billion Guidance: 2024 turnover growth of 7% to 9%; Core operating profit growth of 11% to 13%; Core EPS growth of 10% to 12%. Expected to deliver broadly around the middle of existing ranges

Endlich sind die Streitereien geklärt

Bei mir läuft der Sparplan schön weiter, freue mich schon auf die nächste Dividende 😀

Bleibt trotzdem im Divi-Depot. Bei 16,- hab ich noch ne Order stehen.

Abstufungen aufgrund höherer Risikobewertungen bzgl. der Absatzzahlen für bestimmte Impfstoffe.

17,63 € - 2,5% was ist los?

nur noch 17,95 € - vor vier Wochen noch 20 € - was los hier?

Heute nichtmal 28 €